ArticlePloS one2025
SCO6564, a novel 3-ketoacyl acyl carrier protein synthase III, contributes in fatty acid synthesis in Streptomyces coelicolor.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- MarinePharmaceuticals (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The genus Streptomyces comprises gram-positive bacteria that produce large numbers of secondary metabolites, which have promising commercial applications and deserve extensive study. Most bacteria synthesize fatty acids using a type II fatty acid synthase, with each step catalyzed by a discrete protein. Fatty acid synthesis has been intensively studied in the model strain Streptomyces coelicolor, in which 3-ketoacyl-acyl carrier protein synthase III (KAS III, FabH) is essential for growth and fatty acid biosynthesis. In this study, the FabH homolog SCO6564 (named FabH2) was identified in the S. coelicolor genome by BLAST analysis. The expression of fabH2 restored the growth of Ralstonia solanacearum fabH mutant and made the mutant produce small amounts of branched-chain fatty acids. FabH2 could condense various substrates, including straight-chain and branched-chain acyl-CoAs, with malonyl-acyl carrier protein to initiate fatty acid synthesis in in vitro assays. The fabH2 deletion did not cause significant changes in the growth or fatty acid composition of S. coelicolor, indicating that fabH2 is nonessential for growth or fatty acid synthesis. However, fabH2 overexpression reduced the blue-pigmented actinorhodin production. Phylogenetic analysis of KAS III from different bacteria revealed that FabH2 belongs to a novel group of FabH-type, which is ubiquitous in Streptomyces spp.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.